1. Home
  2. FXHO vs MAIA Comparison

FXHO vs MAIA Comparison

Compare FXHO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FXHO

UTime Limited Class A Ordinary Shares

N/A

Current Price

$10.03

Market Cap

83.2M

Sector

N/A

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.40

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FXHO
MAIA
Founded
N/A
2018
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
79.0M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
FXHO
MAIA
Price
$10.03
$1.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
136.4K
341.3K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.17
$0.87
52 Week High
$25.00
$3.19

Technical Indicators

Market Signals
Indicator
FXHO
MAIA
Relative Strength Index (RSI) 44.94 55.82
Support Level $9.20 $1.36
Resistance Level $15.32 $1.46
Average True Range (ATR) 2.30 0.06
MACD 0.30 0.01
Stochastic Oscillator 39.68 75.00

Price Performance

Historical Comparison
FXHO
MAIA

About FXHO UTime Limited Class A Ordinary Shares

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: